Deals channel feed – Endpoints News

Deals channel feed

Another big biopharma merger runs into another snag at the FTC. What now?

6 years ago

Is the FTC about to force Roche to divest a key hemophilia program before green-lighting Spark buyout?

6 years ago

Regulators throw up another hurdle to Roche’s $4.3B Spark acquisition as questions percolate over hemophilia market domination

6 years ago

Coming out of Chapter 11, Aegerion jumps into welcome arms of Irish pharma with big plans, fresh $60M for its drugs

6 years ago

Ex-Retrophin BD chief flips his rare disease startup onto Nasdaq via reverse merger with Proteon

6 years ago

Lundbeck’s Deborah Dunsire didn’t just want an ex-US deal for Alder’s migraine drug. She wanted the whole world

6 years ago

A long-suffering Clovis makes a leap into radiopharmaceuticals, paying $12M in cash to beef up the pipeline

6 years ago

Boehringer Ingelheim enlists another virtual biotech partner for its foray into retinal diseases

6 years ago

Deborah Dunsire is paying $2B for a chance to leap directly into a blockbuster showdown with a few of the world's biggest pharma giants

6 years ago

From partner to knight in shining armor: Castle Creek to buy Fibrocell

6 years ago

Another pharma giant makes a leap into the global medical marijuana business

6 years ago

Atomwise inks China deal as list of AI collaborations lengthens

6 years ago

After plenty of due diligence, GSK buys one biotech pup in the ‘$500M’ Avalon litter for its pipeline

6 years ago

Australian cell therapy company Mesoblast joins forces with Germany's Grünenthal to tackle low back pain

6 years ago

Shedding non-core units while loading up on cash, Mallinckrodt bags $250M in CDMO sale

6 years ago

Roivant's Vivek Ramaswamy is closing in on a $3B cash deal to sell control of 5 Vants — plus — to Sumitomo Dainippon

6 years ago

Private equity meets China biotech: PAG infuses $540M to gain control of Hisun's biosimilar subsidiary

6 years ago

The IFM team sets up a three-peat as Novartis funds cGAS/STING program — with $840M option to buy

6 years ago

Vertex buys the top spot on the list of the biggest preclinical M&A deals. Were they robbed or was it a steal?

6 years ago

Vertex gambles $950M on biotech buyout, hunting a cure for diabetes

6 years ago

Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?

6 years ago

Worst. biotech. deal. ever? Turns out AbbVie has plenty of competition for that title

6 years ago

Immatics scores $75M upfront in TCR deal with Celgene as interest in tech burgeons

6 years ago

Adaptimmune pledges $312M for Noile-Immune's T cell boosting tech in drive to deliver on TCR promise

6 years ago

First page Previous page 100 101 102103104 105 106 Next page Last page